Results 251 to 260 of about 305,001 (288)

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AML. [PDF]

Future Oncol
Nier S, Pelouchova J, Hills R, Salek S, Derrien H, Chatin S, De La Bigne AM, Vives S, Recher C, Döhner H, Venditti A, Vyas P.   +11 more
europepmc   +1 more source

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics. [PDF]

Cancer Chemother Pharmacol
Brillac C, Sémiond D, Oprea C, Baruchel A, Zwaan CM, Nguyen L.   +5 more
europepmc   +1 more source

Correction to "Isocitrate Dehydrogenase 2 Mutation Promotes Cytarabine Resistance in Acute Myeloid Leukemia by Warburg Effect". [PDF]

Hematol Oncol
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Venetoclax in acute myeloid leukemia

Expert Opinion on Investigational Drugs, 2023
Background: Substantial progress in the therapeutic arsenal used to treat acute myeloid leukemia became possible in the last decade, as a result of advances in gene editing and descriptive and functional genomics. Objective: The aim of this study is to analyze the efficacy and safety of venetoclax in the treatment of acute myeloid leukemia ...
Bruzzese, Antonella, Martino, Enrica Antonia, Mendicino, Francesco, Lucia, Eugenio, Olivito, Virginia, Neri, Antonino, Morabito, Fortunato, Vigna, Ernesto, Gentile, Massimo   +8 more
openaire   +4 more sources

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network, 2008
Approximately 13,290 people will be diagnosed with acute myeloid leukemia (AML) in 2008, and 8820 patients will die of the disease. As the population ages, the incidence of AML, along with myelodysplasia, appears to be rising. Clinical trials have led to significant treatment improvements in some areas, primarily acute promyelocytic leukemia.
Margaret R, O'Donnell, Frederick R, Appelbaum, Steven E, Coutre, Lloyd E, Damon, Harry P, Erba, James, Foran, Jeffrey, Lancet, Lori J, Maness, Guido, Marcucci, Peter G, Maslak, Michael, Millenson, Joseph O, Moore, Farhad, Ravandi, Friedrich, Schuening, Paul, Shami, B Douglas, Smith, Richard M, Stone, Martin S, Tallman, Eunice, Wang, Frank L, White   +19 more
openaire   +5 more sources

Acute Myeloid Leukemia

Hematology, 2001
AbstractThrough the hard work of a large number of investigators, the biology of acute myeloid leukemia (AML) is becoming increasingly well understood, and as a consequence, new therapeutic targets have been identified and new model systems have been developed for testing novel therapies.
F R, Appelbaum, J M, Rowe, J, Radich, J E, Dick   +3 more
openaire   +2 more sources

Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2009
The evolution of acute myeloid leukemia (AML) classification reflects greater understanding of the AML pathogenesis. The 2008 World Health Organization classification incorporated cytogenetic and molecular genetic findings and introduced important prognostic correlations.
Amy, Heerema-McKenney, Daniel A, Arber
openaire   +2 more sources